首站-论文投稿智能助手
典型文献
SMIP-30,a potent and selective PPM1A inhibitor with potential to treat tuberculosis
文献摘要:
Recently,a collaborative research led by Weibo Yang and Jim Sun1 published in Cell Chemical Biology identified a potent and selective small molecule inhibitor(SMIP-30)for human protein phosphatase Mg2+/Mn2+-dependent 1 A(PPM1A).They applied this chemical probe to determine the autophagy receptor p62 as a new substrate of PPM1A,and proved that SMIP-30 could enhance the selective autophagy of macrophages to limit the survival of intracellular Mycobacterium tuberculosis(Mtb)(Fig.1).These findings should promote new therapeutic modalities to overcome tuberculosis(TB)1.
文献关键词:
作者姓名:
Shujing Xu;Xinyong Liu;Peng Zhan
作者机构:
Department of Medicinal Chemistry,Key Laboratory of Chemical Biology,Ministry of Education,School of Pharmaceutical Sciences,Shandong University,Ji'nan 250012,China
引用格式:
[1]Shujing Xu;Xinyong Liu;Peng Zhan-.SMIP-30,a potent and selective PPM1A inhibitor with potential to treat tuberculosis)[J].药学学报(英文版),2022(12):4519-4521
A类:
SMIP,PPM1A,Sun1
B类:
selective,inhibitor,potential,treat,tuberculosis,Recently,collaborative,research,led,by,Weibo,Yang,Jim,published,Cell,Chemical,Biology,identified,small,molecule,human,protein,phosphatase,Mg2+,Mn2+,dependent,They,applied,this,chemical,probe,determine,autophagy,receptor,p62,new,substrate,proved,that,could,enhance,macrophages,limit,survival,intracellular,Mycobacterium,Mtb,Fig,These,findings,should,promote,therapeutic,modalities,overcome,TB
AB值:
0.632623
相似文献
Pharmacological inhibition of MyD88 suppresses inflammation in tubular epithelial cells and prevents diabetic nephropathy in experimental mice
Qiu-yan Zhang;Su-jing Xu;Jian-chang Qian;Li-bin Yang;Peng-qin Chen;Yi Wang;Xiang Hu;Ya-li Zhang;Wu Luo;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Medical Research Center,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China;School and Hospital of Stomatology,Wenzhou Medical University,Wenzhou 325027,China;Department of Endocrinology,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Xiao-ru Zhou;Xiao Li;Li-ping Liao;Jie Han;Jing Huang;Jia-cheng Li;Hong-ru Tao;Shi-jie Fan;Zhi-feng Chen;Qi Li;Shi-jie Chen;Hong Ding;Ya-xi Yang;Bing Zhou;Hua-liang Jiang;Kai-xian Chen;Yuan-yuan Zhang;Chuan-xin Huang;Cheng Luo-Drug Discovery and Design Center,The Center for Chemical Biology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 200031,China;Department of Medicinal Chemistry,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Shanghai Institute of Immunology and Department of Immunology and Microbiology,Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,Faculty of Basic Medicine,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants
Hong Wang;Zhe Chang;Guo-di Cai;Ping Yang;Jiang-he Chen;Shan-shu Yang;Yin-feng Guo;Ming-yu Wang;Xue-hua Zheng;Jin-ping Lei;Pei-qing Liu;De-peng Zhao;Jun-jian Wang-School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China;Department of Pathology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Key Laboratory of Molecular Target and Clinical Pharmacology,School of Pharmaceutical Sciences and the Fifth Affiliated Hospital,Guangzhou Medical University,Guangzhou 510006,China;Guangdong Provincial Key Laboratory of New Drug Design and Evaluation,School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation,Sun Yat-sen University,Guangzhou 510006,China
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity
Chuan-jing Cheng;Kai-xin Liu;Man Zhang;Fu-kui Shen;Li-li Ye;Wen-bo Wu;Xiao-tao Hou;Er-wei Hao;Yuan-yuan Hou;Gang Bai-State Key Laboratory of Medicinal Chemical Biology,College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research,Nankai University,Tianjin 300353,China;Collaborative Innovation Center of Research on Functional Ingredients from Agricultural Residues,Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica,Guangxi University of Chinese medicine,Nanning 530200,China;China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research,Guangxi University of Chinese Medicine,Nanning 530200,China
Discovery of novel MIF inhibitors that attenuate microglial inflammatory activation by structures-based virtual screening and in vitro bioassays
Yu Zhang;Lei Xu;Yao Zhang;Jie Pan;Pu-qing Wang;Sheng Tian;Huan-ting Li;Bo-wen Gao;Ting-jun Hou;Xue-chu Zhen;Long-Tai Zheng-Department of Pharmacy,Hubei Clinical Research Center of Parkinson's disease,Xiangyang Key Laboratory of Movement Disorders,Xiangyang No.1 People'Hospital,Hubei University of Medicine,Xiangyang 441000,China;Institute of Bioinformatics and Medical Engineering,Jiangsu University of Technology,Changzhou 213001,China;Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences,Soochow University,Suzhou 215123,China;School of Pharmacy,Baotou Medical College,Baotou 014060,China;College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China
Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening
Xue-ping Hu;Liu Yang;Xin Chai;Yi-xuan Lei;Shah Alam;Lu Liu;Chao Shen;De-jun Jiang;Zhe Wang;Zhi-yong Liu;Lei Xu;Kang-lin Wan;Tian-yu Zhang;Yue-lan Yin;Dan Li;Dong-sheng Cao;Ting-jun Hou-Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China;State Key Lab of CAD&CG,Zhejiang University,Hangzhou 310058,China;State Key Laboratory of Respiratory Disease,Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou 510530,China;University of Chinese Academy of Sciences,Beijing 100049,China;Xiangya School of Pharmaceutical Sciences,Central South University,Changsha 410013,China;Institute of Bioinformatics and Medical Engineering,School of Electrical and Information Engineering,Jiangsu University of Technology,Changzhou 213001,China;State Key Laboratory of Infectious Disease Prevention and Control,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,National Institute for Communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China;Jiangsu Key Laboratory of Zoonosis,Yangzhou University,Yangzhou 225009,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。